Attorney Docket No. 1276-37

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS: Kannan et al.

Examiner: (Not Yet Assigned)

SERIAL NO.:

10/762,180

Group: Art Unit: 1615

FILED:

January 21, 2004

Dated: August 9, 2004

FOR:

CONTROLLED RELEASE MODIFYING COMPLEX

AND PHARMACEUTICAL COMPOSITIONS THEREOF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Applicants' duty of disclosure, the information listed in the attached Form PTO-1449 is brought to the attention of the Examiner.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on <u>August 9</u>, <u>2004</u>.

Dated: August 9, 2004

Michael E. Carmen

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

To the best of Applicants knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action on the merits in connection with this case.

Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account <u>04-1121</u>. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. <u>04-1121</u> therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably distinguishable over the prior art and to be in condition for allowance. Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,

Michael E. Carmen Reg. No. 43,533

Attorney for Applicants

DILWORTH & BARRESE, LLP 333 Earle Ovington Blvd. Uniondale, NY 11553 (516) 228-8484 (516) 228-8516 (fax)

Sneet 1 of 1,	<u> </u>						
Form PTO-1449	FORM PTO-1449 U.S. DEPARTMENT OF CO. PATENT AND TRADEMARK		ATTY. DOCKET NO. 1276-37	SERIAL NO. 10/762,180			
2001			APPLICANTS Kannan et al.				
AUB 1 2004 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			FILING DATE January 21, 2004		GROUP ART UNIT 1615		
					-		
		U.S. P/	ATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLAS	SS SUBCLASS	FILING IF APPR	G DATE
	4,389,393	06/21/83	SCHOR ET AL.				
	4,540,566	09/10/85	DAVIS ET AL.	116.6			
	4,808,411	02/28/89	LU ET AL.				
	5,393,765	02/28/95	INFELD ET AL.			~~~	
	5,705,190	01/06/98	BROAD ET AL.				
	6,010,718	01/04/00	AL-RAZZAK ET AL.				

				<u> </u>			
				ļ			
		451-		-			
		FORETCH	PATENT DOCUMENTS				
	DOCUMENT NUMBER DATE		COUNTRY CLA		SS SUBCLASS	TRANSLATION	
						YES	NO
				·			
	OTHER PRI	OR ART (Including Auth	or, Title, Date, Pertinent	Pages,	Etc.)		
							_
					7-70	*,	
EXAMINER			DATE CONSIDERED				
* EXAMINER: In Draw line thro communication	ugh citation if not in co	dered, whether or not on onformance and not con-	citation is in conformance sidered. Include copy of	with Mi this for	PEP 609.		

(Form PTO-1449 [6-4])